Zyflamend™

• Weak evidenceone or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects (this is the CancerChoices definition; other researchers and studies may define this differently) of lower prostate-specific antigen (PSA) levels in a man with castration-resistant prostate cancer and exponentially increasing PSA levels treated with Zyflamend

See How can Zyflamend help you? What the research says ›

• Weak evidenceone or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects (this is the CancerChoices definition; other researchers and studies may define this differently) of lower markers of inflammation among men with high-grade prostatic intraepithelial neoplasia (HGPIN) treated with Zyflamend
• No evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments on testosterone levels among men with high-grade prostatic intraepithelial neoplasia (HGPIN) treated with Zyflamend

See How can Zyflamend help you? What the research says ›

• Weak evidenceone or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects (this is the CancerChoices definition; other researchers and studies may define this differently) of less arthritic pain and better well-being in a man with castration-resistant prostate cancer treated with Zyflamend

See How can Zyflamend help you? What the research says ›

• Weak evidenceone or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects (this is the CancerChoices definition; other researchers and studies may define this differently) of lower or stable prostate-specific androgen (PSA) levels and reversal of high-grade prostatic intraepithelial neoplasia in men treated with Zyflamend

See How can Zyflamend help you? What the research says ›

• Not used in any of our program sources
• Not mentioned in oncology clinical practice guidelines
• Limited mention by an authoritative cancer organization

See How integrative experts use Zyflamend ›

• Generally safe, with only minor side effects
• Use is not recommended among pregnant or lactating women

See Safety and precautions ›

• Widely available without restriction and 
• Low to moderate cost (below $2000 US/year), depending on dosage

See Affordability and access ›